Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA
Enanta Pharmaceuticals — XIX International Symposium on Respiratory Viral Infections 2017
16 slides from Enanta Pharmaceuticals's conference presentation, Jun 25, 2017
Slide 1: EDP-938, a Novel Non-Fusion Replication Inhibitor of RSV
XIX International Symposium on Respiratory Viral Infections June 22-25, 2017 Berlin Germany From Chemistry to Cures EDP-938, a Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities both In Vitro and In Vivo Kai Lin, Ph.D. June 25th, 2017 ENAN
Slide 2: There remains a significant unmet medical need with RSV infection
There remains a significant unmet medical need with RSV infection • Leading cause of LRTI in infants & elderly Potential pool of patients (per year) who may seek RSV treatments3 - Almost all infants infected by the age of three • 3.4m hospitalizations, 200k deaths/year worldwide1 - ElderIy with unde
Slide 3: RSV life cycle & antiviral targets
RSV life cycle & antiviral targets A replication inhibitor may offer the advantage of being effective given post-infection, i.e. therapeutically Entry Inhibitors Anti-F mAb: Replication Inhibitors Synagis MEDI-8897 L inhibitors: Nucleoside: REGN-2222 YM-53403 ALS-8176 ALX-0171 AZ-27 PC-786 N inhibit
Slide 4: A novel potent RSV N inhibitor
EDP-938: A novel potent RSV N inhibitor RSV-604: the previous known RSV nucleoprotein (N) inhibitor* • In vitro resistance selection mapped to RSV N protein but exact MoA unclear • Clinical PoC efficacy demonstrated : 2.31-log viral load reduction after 5-day treatment in a sub-population of RSV i
Slide 5: EDP-938 potently inhibits all RSV lab strains tested in vitro
EDP-938 potently inhibits all RSV lab strains tested in vitro Virus Assay EC50 (nM) EC90 (nM) Sub- Read- Strain Cell RSV-604 EDP-938 RSV-604 EDP-938 type out HBEC PCR 563 ± 308 23 ± 13 772 ± 389 36 ± 17 M37 HEp-2 PCR 1900 ± 436 54 ± 5 3474 ± 2028 85 ± 21 HEp-2 CPE 980 ± 150 28 ± 4 1314 ± 115 34 ± 10
Slide 6: EDP-938 is also highly active against RSV-A and B clinical isolates
EDP-938 is also highly active against RSV-A and B clinical isolates EC50 (nM) Clinical Isolates RSV-604 EDP-938 RSV-A (n=14) 2,121 ± 2,189 76 ± 37 RSV-B (n=11) 1,264 ± 509 121 ± 45 ENANTA Pharmaceuticals © 2017 |66
Slide 7: EDP-938 maintains antiviral activity against RSV even if given post-infection in vitro
EDP-938 maintains antiviral activity against RSV even if given post-infection in vitro HEp-2 cells were treated with EDP-938 at 2h before or 2, 6 and 24h after infection with RSV-A Long at MOI=0.1 120 100 Cell Viability (%) 80 -2 hr (n=6) 60 2 hr (n=6) 40 6 hr (n=6) 20 24 hr (n=3) 0 EDP-938 [M]
Slide 8: EDP-938 presents a high barrier to resistance and no cross-resistance
EDP-938 presents a high barrier to resistance and no cross-resistance to other RSV inhibitors • Resistant virus can only be selected with EDP-938 starting at low concentration of the drug (1xEC50) followed by a slow increase to 16xEC50 after multiple passages • Selection with higher concentration of
Slide 9: The anti-RSV effect of EDP-938 appears to be mediated through viral N protein
The anti-RSV effect of EDP-938 appears to be mediated through viral N protein RSV N31-252 crystal structure Mutations selected with EDP-938 located in P-binding domain • Mutations selected in vitro with EDP-938 mainly localized in RSV N protein (similarly to previous report with RSV-604), suggesting
Slide 10: Combinations of EDP-938 with other RSV inhibitors result in stronger antiviral effect
Combinations of EDP-938 with other RSV inhibitors result in stronger antiviral effect than single agents EDP-938 + EDP-938 EDP-938 + Fusion Inhibitor EDP-938 (M) EDP-938 (M) EDP-938 (M) GS-5806 (M) EDP-938 + L Inhibitor EDP-938 + Nuc • RSV-A Long • HEp-2 cells • MOI=0.1 • CPE assay EDP-938 (M)
Slide 11: The effects of combinations are moderately synergistic
The effects of combinations are moderately synergistic Analysis using Loewe additivity model Ave. Combination Index (CI) at Compounds EC50 EC75 EC90 EC95 Ave. EDP-938 + EDP-938 0.8 0.8 0.9 0.9 0.9 EDP-938 + ALS-8112 0.7 0.6 0.5 0.4 0.6 EDP-938 + AZ-27 0.8 0.6 0.5 0.4 0.6 EP-938 + GS-5806 0.9 0.7 0.6
Slide 12: Evaluating in vivo efficacy of EDP-938 in African Green Monkey model
Evaluating in vivo efficacy of EDP-938 in African Green Monkey model African Green Monkey (AGM) model selected for evaluating in vivo efficacy of EDP-938, because • Permissive for human RSV infection • Support RSV replication at a higher level than cotton rats and BALB/c mice • Model validated for
Slide 13: EDP-938 demonstrated excellent in vivo efficacy in the AGM model
EDP-938 demonstrated excellent in vivo efficacy in the AGM model LOD (limit of detection) = 100 copies/mL ENANTA Pharmaceuticals © 2017 13 | 13
Slide 14: 4-log viral load reduction in both BAL and NP swab in treated AGMs
There was a 4-log viral load reduction in both BAL and NP swab in EDP-938 treated AGMs BAL Viral Load on Day 5 NP Swab Viral Load on Day 7 LOD* * Limit of Detection (LOD) = 100 copies/mL ENANTA Pharmaceuticals © 2017 14 | 14
Slide 15: EDP-938 Summary
EDP-938 Summary A novel non-fusion replication inhibitor that appears to modulate the RSV N protein Highly active against all RSV-A and B strains and clinical isolates Inhibits RSV at a post-entry replication step and is effective given post infection, i.e. therapeutically Presents a high ba
Slide 16: Acknowledgement
Acknowledgement Michael Rhodin In Jong Kim Nicole McAllister Jianming Yu Susan Clugston Tom Blaisdell Jonathan Castillo Joe Panarese Solymar Negretti-Emmanuel Kellye Daniels Kevin McGrath Lijuan Jiang Brian Shook Andrew Hague Matthew Ronsheim Pedro Piedra (Baylor University) Kelly Henrickson (Medica
Enanta Pharmaceuticals — XIX International Symposium on Respiratory Viral Infections 2017 on 6ix